Non-surgical Approaches in the Treatment of Lower Back Pain: A Review of Methods, Efficacy, and Safety
DOI:
https://doi.org/10.12775/QS.2025.43.61483Keywords
back pain, LBP, non-pharmacological interventions, pharmacological treatment, efficacy, Safety, chronic back pain, review, treatment methods, chronic low back painAbstract
Low back pain (LBP) is among the most common musculoskeletal disorders globally, representing a leading cause of disability and healthcare expenditure. Its prevalence is expected to rise significantly in the coming decades, emphasizing the need for effective, evidence-based treatment strategies. This narrative review explores non-surgical approaches to LBP management, focusing on pharmacological and non-pharmacological therapies. It discusses the classification, pathophysiology, and red flag symptoms, alongside an evaluation of conservative treatments including NSAIDs, acetaminophen, muscle relaxants, opioids, antidepressants, physical therapy, acupuncture, spinal manipulation, and psychosocial interventions. The findings indicate that NSAIDs offer modest short-term relief and remain first-line pharmacological agents, while acetaminophen has limited efficacy. Muscle relaxants may benefit acute cases but carry notable side effects, particularly in older adults. Opioids, though effective in the short term, show minimal long-term benefit and a high risk of dependence. Non-pharmacological treatments—especially exercise therapy, manual therapy, and cognitive-behavioral interventions—demonstrate consistent efficacy in reducing pain and improving function. In conclusion, optimal management of LBP necessitates an individualized, multimodal approach that integrates pharmacological options with physical and psychological strategies to minimize harm, enhance function, and address biopsychosocial contributors to pain.
References
REFERENCES:
1. Cypress BK. Characteristics of physician visits for back symptoms: a national perspective. Am J Public Health. 1983;73(4):389–95.
Cunningham LS, Kelsey JL. Epidemiology of musculoskeletal impairments and associated disability. Am J Public Health. 1984;74(6):574–9. doi:10.2105/ajph.74.6.574. PMID: 6232862; PMCID: PMC1651655.
2. Frymoyer JW. Back pain and sciatica. N Engl J Med. 1988;318(5):291–300. doi:10.1056/NEJM198802043180506.
3. Tucker HR, Scaff K, McCloud T, Carlomagno K, Daly K, Garcia A, et al. Harms and benefits of opioids for management of non-surgical acute and chronic low back pain: a systematic review. British Journal of Sports Medicine [Internet]. 2019 Mar 22;54(11):bjsports-2018-099805.
5. Wenig CM, Schmidt CO, Kohlmann T, Schweikert B. Costs of back pain in Germany. Eur J Pain. 2009;13(3):280–6. doi:10.1016/j.ejpain.2008.04.005. PMID: 18524652.
6. Rusiński K, Klimas F, Zatłoka-Mazur D, Sienkiewicz M, Pawłowski B, Potoczek A, et al. Low back pain – a review. Qual Sport [Internet]. 2025 Feb 17;38:57930. https://doi.org/10.12775/QS.2025.38.57930
7. Rulewska NM, Grabowski F, Michalak K, Janowski K, Neska D. Cupping therapy on low back pain. A systematic review. Qual Sport [Internet]. 2025 May 10;41:59807. https://doi.org/10.12775/QS.2025.41.59807
8. Kim HS, Wu PH, Jang IT. Lumbar degenerative disease Part 1: Anatomy and pathophysiology of intervertebral discogenic pain and radiofrequency ablation of basivertebral and sinuvertebral nerve treatment for chronic discogenic back pain. Int J Mol Sci. 2020;21(4):1483. doi:10.3390/ijms21041483.
9. Deyo RA, Weinstein JN. Low back pain. N Engl J Med. 2001;344(5):363–70. doi:10.1056/NEJM200105243442307.
10. Maher C, Underwood M, Buchbinder R. Non-specific low back pain. Lancet. 2017;389(10070):736–47. doi:10.1016/S0140-6736(16)30970-9.
11. Verhagen AP, Downie A, Popal N, Maher C, Koes BW. Red flags presented in current low back pain guidelines: a review. Eur Spine J. 2016;25(9):2788–802. doi:10.1007/s00586-016-4684-0.
12. Henschke N, Maher CG, Refshauge KM, et al. Prevalence of and screening for serious spinal pathology in patients presenting to primary care settings with acute low back pain. Arthritis Rheum. 2009;60(10):3072–80. doi:10.1002/art.24853.
13. Williams CM, Henschke N, Maher CG, van Tulder MW, Koes BW, Macaskill P, et al. Red flags to screen for vertebral fracture in patients presenting with low-back pain. Cochrane Database Syst Rev. 2023;11:CD008643. doi:10.1002/14651858.CD008643.pub3.
14. Ramsook RR, Malanga GA. Myofascial low back pain. Curr Pain Headache Rep. 2012;16(5):423–32. doi:10.1007/s11916-012-0290-y. PMID: 22945480.
15.Mense S. Referral of muscle pain. J Am Phys Soc. 1994;3:1–9.
16. Simons DG. New views of myofascial trigger points: etiology and diagnosis. Arch Phys Med Rehabil. 2008;89:157–9.
17. Shah JP, Gilliams EA. Uncovering the biochemical milieu of myofascial trigger points using in vivo microdialysis: an application of muscle pain concepts to myofascial pain syndrome. J Bodyw Mov Ther. 2008;12(4):371–84.
18. Shah JP, Danoff JV, Desai MJ, et al. Biochemicals associated with pain and inflammation are elevated in sites near to, and remote from active myofascial trigger points. Arch Phys Med Rehabil. 2008;89:16–23.
19. Remotti E, Nduaguba C, Woolley PA, et al. Discogenic back pain: update on treatment. Orthop Rev (Pavia). 2023;15. doi:10.52965/001c.84649. PMID: 37641793.
20. Gunzburg R, Parkinson R, Moore R, Cantraine F, Hutton W, Vernon-Roberts B, et al. A cadaveric study comparing discography, magnetic resonance imaging, histology, and mechanical behavior of the human lumbar disc. Spine (Phila Pa 1976). 1992;17(4):417–26.
21. Muthupillai R, Lomas DJ, Rossman PJ, et al. Magnetic resonance elastography by direct visualization of propagating acoustic strain waves. Science. 1995;269:1854–7.
22. Schliessbach J, Siegenthaler A, Haeni M, et al. Blockade of the sinuvertebral nerve for the diagnosis of lumbar diskogenic pain: an exploratory study. Anesth Analg. 2010;111(1):204–6.
23. Kallewaard JW, Groen GJ, Racz GB, van Kleef M, Mekhail N. Discogenic low back pain. In: Evidence-Based Interventional Pain Medicine: According to Clinical Diagnoses. 1st ed. 2011. p. 107–22.
24. Zawilla NH, Darweesh H, Mansour N, Helal S, Taha FM, Awadallah M, et al. Matrix metalloproteinase-3, vitamin D receptor gene polymorphisms, and occupational risk factors in lumbar disc degeneration. J Occup Rehabil. 2014;24:370–81.
25. Jhawar BS, Fuchs CS, Colditz GA, Stampfer MJ. Cardiovascular risk factors for physician-diagnosed lumbar disc herniation. Spine J. 2006;6(6):684–91. doi:10.1016/j.spinee.2006.04.016. PMID: 17088199.
26. Eisenstein SM, Parry CR. The lumbar facet arthrosis syndrome: clinical presentation and articular surface changes. J Bone Joint Surg Br. 1987;69:3–7.
27. Urits I, Burshtein A, Sharma M, Testa L, Gold PA, Orhurhu V, et al. Low back pain, a comprehensive review: pathophysiology, diagnosis, and treatment. Curr Pain Headache Rep. 2019;23(3):23. doi:10.1007/s11916-019-0757-1. PMID: 30854609.
28. Battié MC, Videman T, Gibbons LE, Fisher LD, Manninen H, Gill K. Determinants of lumbar disc degeneration: a study relating lifetime exposures and magnetic resonance imaging findings in identical twins. Spine. 1995;20(24):2601–12.
29. Wilkinson HA. The failed back syndrome: etiology and therapy. 2nd ed. Philadelphia: Harper & Row; 1991.
30. Waguespack A, Schofferman J, Slosar P, Reynold J. Etiology of long-term failures of lumbar spine surgery. Pain Med. 2002;3:18–22.
31. Orhurhu V, Urits I, Olusunmade M, Owais K, Jones M, Galasso A, et al. Trends of comorbid depression in hospitalized patients with failed back surgery syndrome: an analysis of the nationwide inpatient sample. Pain Ther. 2018;7:217–26.
32. Chan C. Failed back surgery syndrome: review article. Pain Med. 2011;12:577–606.
33. Weinstein JN, Lurie JD, Tosteson TD, Hanscom B, Tosteson ANA, Blood EA, et al. Surgical versus nonsurgical treatment for lumbar degenerative spondylolisthesis. N Engl J Med. 2007;356:2257–70.
34. Fritzell P, Hägg O, Nordwall A; Swedish Lumbar Spine Study Group. Complications in lumbar fusion surgery for chronic low back pain: comparison of three surgical techniques used in a prospective randomized study. Eur Spine J. 2003;12(2):178–89.
35. Weber H. Lumbar disc herniation: a controlled, prospective study with ten years of observation. Spine. 1983;8:131–40.
36. Buelt A, McCall S, Coster J. Management of low back pain: guidelines from the VA/DoD. Am Fam Physician. 2023;107(4):435–7. PMID: 37054430.
37. Qaseem A, Wilt TJ, McLean RM, Forciea MA. Noninvasive treatments for acute, subacute, and chronic low back pain: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2017;166(7):514–30. doi:10.7326/M16-2367.
38. Cabioglu MT, Ergene N, Tan U. The mechanism of acupuncture and clinical applications. Int J Neurosci. 2006;116(2):115–25. doi:10.1080/00207450500341472.
39. Manheimer E, White A, Berman B, Forys K, Ernst E. Meta-analysis: acupuncture for low back pain. Ann Intern Med. 2005;142(8):651–63. doi:10.7326/0003-4819-142-8-200504190-00014.
40. Cashin AG, Rizzo RRN, Wand BM, O'Connell NE, Lee H, Bagg MK, et al. Non‐pharmacological and non‐surgical treatments for low back pain in adults: an overview of Cochrane Reviews. Cochrane Database Syst Rev. 2021;8:CD014691. doi:10.1002/14651858.CD014691.
41. Paige NM, Miake-Lye IM, Booth MS, et al. Association of spinal manipulative therapy with clinical benefit and harm for acute low back pain: systematic review and meta-analysis. JAMA. 2017;317(14):1451–60. doi:10.1001/jama.2017.3086.
42. Coulter ID, Crawford C, Hurwitz EL, Vernon H, Khorsan R, Suttorp Booth M, et al. Manipulation and mobilization for treating chronic low back pain: a systematic review and meta-analysis. Spine J. 2018;18(5):866–79. doi:10.1016/j.spinee.2018.01.013. PMID:29371112; PMCID:PMC6020029.
43. Bialosky JE, Bishop MD, Price DD, Robinson ME, George SZ. The mechanisms of manual therapy in the treatment of musculoskeletal pain: a comprehensive model. Man Ther. 2009;14(5):531–8. doi:10.1016/j.math.2008.09.001. PMID:19027342; PMCID:PMC2775050.
44. Furlan AD, Imamura M, Dryden T, Irvin E. Massage for low-back pain. Cochrane Database Syst Rev. 2008;(4):CD001929. doi:10.1002/14651858.CD001929.pub2. PMID:18843627.
45. Farasyn A, Meeusen R, Nijs J. A pilot randomized placebo-controlled trial of roptrotherapy in patients with subacute non-specific low back pain. J Back Musculoskelet Rehabil. 2006;19:111–7.
46. Yoon YS, Yu KP, Lee KJ, Kwak SH, Kim JY. Development and application of a newly designed massage instrument for deep cross-friction massage in chronic non-specific low back pain. Ann Rehabil Med. 2012;36(1):55–65. doi:10.5535/arm.2012.36.1.55. PMID:22506236.
47. van Middelkoop M, Rubinstein SM, Kuijpers T, et al. A systematic review on the effectiveness of physical and rehabilitation interventions for chronic non-specific low back pain. Eur Spine J. 2011;20:19–39. doi:10.1007/s00586-010-1518-3.
48. Ebadi S, Henschke N, Forogh B, Nakhostin Ansari N, van Tulder MW, Babaei-Ghazani A, et al. Therapeutic ultrasound for chronic low back pain. Cochrane Database Syst Rev. 2020;7:CD009169. doi:10.1002/14651858.CD009169.pub3.
49. Allen C, Jenkinson C, et al. Bed rest: a potentially harmful treatment needing more careful evaluation. Lancet. 1999;354(9186):1229–33.
50. Pincus T, Burton AK, Vogel S, Field AP. A systematic review of psychological factors as predictors of chronicity/disability in prospective cohorts of low back pain. Spine. 2002;27(5):E109–20.
51. National Institute for Health and Care Excellence (NICE). Low back pain and sciatica in over 16s: assessment and management. NICE Guideline [NG59]. 2020.
52. Ehde DM, Dillworth TM, Turner JA. Cognitive-behavioral therapy for individuals with chronic pain: efficacy, innovations, and directions for research. Am Psychol. 2014;69(2):153–66.
53. Hinz B, Cheremina O, Brune K. Acetaminophen (paracetamol) is a selective cyclooxygenase-2 inhibitor in man. FASEB J. 2008;22(2):383–90. doi:10.1096/fj.07-8506com.
54. Chandrasekharan NV, Dai H, Roos KL, et al. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci USA. 2002;99(21):13926–31. doi:10.1073/pnas.162468699.
55. Pickering G, Loriot MA, Libert F, Eschalier A, Beaune P, Dubray C. Paracetamol and central serotonergic mechanisms of pain control. Fundam Clin Pharmacol. 2006;20(1):1–7. doi:10.1111/j.1472-8206.2006.00378.x.
56. Pini LA, Sandrini M, Vitale G, Ottani A, Bertolini A. Central analgesic effect of paracetamol: involvement of serotoninergic pathways. Eur J Pharmacol. 1997;331(2–3):145–52. doi:10.1016/S0014-2999(96)00944-8.
57. Högestätt ED, Jönsson BAG, Ermund A, et al. Conversion of acetaminophen to the bioactive N-acylphenolamine AM404 via fatty acid amide hydrolase-dependent arachidonic acid conjugation in the nervous system. J Biol Chem. 2005;280(36):31405–12.
58. Mallet C, Barrière DA, Ermund A, et al. TRPV1 in brain is involved in acetaminophen-induced antinociception. PLoS One. 2008;3(9):e3383.
59. Williams CM, Maher CG, Latimer J, et al. Efficacy of paracetamol for acute low-back pain: a double-blind, randomised controlled trial. Lancet. 2014;384(9954):1586–96.
60. Machado GC, Maher CG, Ferreira PH, et al. Paracetamol for low back pain. Cochrane Database Syst Rev. 2016;6:CD012230. doi:10.1002/14651858.CD012230.
61. Larson AM. Acetaminophen hepatotoxicity. Clin Liver Dis. 2007;11(2):525–48. doi:10.1016/j.cld.2007.03.006.
62. World Health Organization. WHO guidelines on the pharmacological treatment of persisting pain in adults with medical illnesses. Geneva: WHO; 2012.
63. National Institute for Health and Care Excellence (NICE). Low back pain and sciatica in over 16s: assessment and management. NICE guideline [NG59]. 2020.
64. van Tulder M, Touray T, Furlan AD, Solway S, Bouter L. Muscle relaxants for non-specific low back pain: a systematic review within the framework of the Cochrane Collaboration. Spine. 2003;28(17):1978–92. doi:10.1097/01.BRS.0000085300.14866.4F.
65. Derry S, Wiffen PJ, Moore RA. Oral nonsteroidal anti-inflammatory drugs (NSAIDs) for neuropathic pain in adults. Cochrane Database Syst Rev. 2017;7:CD012182. doi:10.1002/14651858.CD012182.pub2.
66. Gierek M, Madej D, Nowak S. Rola prostaglandyn w mechanizmach bólu. Anestezjol Ratown. 2019;13:214–20.
67. van der Gaag WH, Roelofs PDDM, Enthoven WTM, van Tulder MW, Koes BW. Non-steroidal anti-inflammatory drugs for acute low back pain. Cochrane Database Syst Rev. 2020;4:CD013581. doi:10.1002/14651858.CD013581.
68. Cochrane Rehabilitation. Do non-steroidal anti-inflammatory drugs (NSAIDs) provide clinical benefits in the treatment of acute low back pain? [Internet]. Available from: https://rehabilitation.cochrane.org/do-non-steroidal-anti-inflammatory-drugs-nsaids-provide-clinical-benefits-treatment-acute-low-back
69. Enthoven WTM, Roelofs PDDM, Deyo RA, van Tulder MW, Koes BW. Non-steroidal anti-inflammatory drugs for chronic low back pain. Cochrane Database Syst Rev. 2016;2:CD012087. doi:10.1002/14651858.CD012087.
70. Koes BW, Backes D, Bindels PJE. Pharmacotherapy for chronic non-specific low back pain: current and future options. Expert Opin Pharmacother. 2018;19(5):517–23. doi:10.1080/14656566.2018.1454430.
71. Malfertheiner P, Chan FKL, McColl KEL. Peptic ulcer disease. Lancet. 2009;374(9699):1449–61.
72. Fitzgerald GA. Coxibs and cardiovascular disease. N Engl J Med. 2004;351(17):1709–11. doi:10.1056/NEJMp048288. PMID: 15470192.
73. Urbański W, Dolata N, Balcer B, Kruczkowska A, Bulzacki E, Cebula A, et al. NSAIDs in sports medicine: balancing quick relief with long-term health impacts. Qual Sport [Internet]. 2024 Dec 24;36:56892. https://doi.org/10.12775/QS.2024.36.56892
74. Leão Nunes Filho MJ, Barreto ESR, Antunes Júnior CR, Alencar VB, Falcão Lins-Kusterer LE, Azi LMTA, et al. Efficacy of antidepressants in the treatment of chronic nonspecific low back pain: a systematic review and meta-analysis. Pain Manag. 2024;14(8):437–51. doi:10.1080/17581869.2024.2408215. PMID: 39377458; PMCID: PMC11487954.
75. Ferraro MC, Urquhart DM, Ferreira GE, Wewege MA, Abdel Shaheed C, Traeger AC, et al. Antidepressants for low back pain and spine-related leg pain. Cochrane Database Syst Rev. 2025;3:CD001703. doi:10.1002/14651858.CD001703.pub4.
76. Chou R, Turner JA, Devine EB, et al. The effectiveness and risks of long-term opioid therapy for chronic pain: a systematic review for a National Institutes of Health Pathways to Prevention Workshop. Ann Intern Med. 2015;162(4):276–86.
77. Chaparro LE, Furlan AD, Deshpande A, Mailis-Gagnon A, Atlas S, Turk DC. Opioids compared to placebo or other treatments for chronic low-back pain. Cochrane Database Syst Rev. 2013;8:CD004959. doi:10.1002/14651858.CD004959.pub4. PMID: 23983011; PMCID: PMC11056234.
78. Ballantyne JC, LaForge SK. Opioid dependence and addiction during opioid treatment of chronic pain. Pain. 2007;129(3):235–55. doi:10.1016/j.pain.2007.03.028. PMID: 17482363.
79. Krebs EE, Gravely A, Nugent S, et al. Effect of opioid vs nonopioid medications on pain-related function in patients with chronic back pain or hip or knee osteoarthritis pain: the SPACE randomized clinical trial. JAMA. 2018;319(9):872–82. doi:10.1001/jama.2018.0899.
80. Browning R, Jackson JL, O'Malley PG. Cyclobenzaprine in the treatment of acute low back pain: a meta-analysis. Arch Fam Med. 2001;10(2):156–60.
81. Abdel Shaheed C, Maher CG, McLachlan AJ. Efficacy, tolerability, and safety of muscle relaxants for low back pain: systematic review and meta-analysis of randomised controlled trials. BMJ. 2021;374:n1446.
82. Cashin AG, Folly T, Bagg MK, et al. Safety of muscle relaxants for low back pain: a systematic review and meta-analysis. Br J Gen Pract. 2021;71(712):e209–e218.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Tomasz Karol Książek, Aleksandra Szeliga, Piotr Mikołaj Dembicki , Anna Ewelina Francuziak, Kinga Kozłowska , Maciej Borowski, Natalia Dzieszko , Michał Szczepański, Weronika Kalinowska, Paulina Sara Kulasza
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 523
Number of citations: 0
